Allergy Therapeutics' latest data highlights benefits of adjuvant technology

Commercial biotechnology firm Allergy Therapeutics on Monday published new data highlighting its technology’s effectiveness as an adjuvant compared to existing treatments.

According to Allergy Therapeutics, the study data published highlights the company’s microcrystalline tyrosine (MCT) as a suitable and flexible alternative to aluminium hydroxide in allergen specific immunotherapy and infectious disease applications.

Matthias Kramer, Allergy Therapeutics' international medical director and co-author of the paper, said: "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines."

Adjuvants stimulate an immune response to antigens and allow the body to rapidly respond to threats.

"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines," said Kramer.

Additionally, the company is currently undergoing studies with a cancer (melanoma) model.

As of 1337 BST, Allergy Therapeutics’ shares were up 3.16% at 24.50p.